ST Pharm Co.,Ltd. (KOSDAQ:237690)

Market Cap	1.87T
Revenue (ttm)	298.11B
Net Income (ttm)	33.94B
Shares Out	20.70M
EPS (ttm)	1,686.44
PE Ratio	53.54
Forward PE	36.26
Dividend	500.00 (0.56%)
Ex-Dividend Date	Dec 27, 2024

Volume	116,789
Average Volume	134,532
Open	88,800
Previous Close	88,800
Day's Range	87,100 - 91,300
52-Week Range	66,600 - 113,500
Beta	0.43
RSI	46.19
Earnings Date	Oct 31, 2025

About ST Pharm

ST Pharm Co.,Ltd., provides custom manufacturing services for active pharmaceutical ingredient and intermediates in South Korea and internationally. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical R and D solutions. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co....

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1983
• Employees: 655
• Stock Exchange: KOSDAQ
• Ticker Symbol: 237690

Financial Performance

In 2024, ST Pharm's revenue was 273.75 billion, a decrease of -3.94% compared to the previous year's 284.99 billion. Earnings were 34.71 billion, an increase of 77.27%.